Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Bicycle Therapeutics
(NASDAQ:BCYC)
Intraday
$21.82
0
[0.00%]
After-Hours
$21.82
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$21.82
0
[0.00%]
At close: Apr 17
$21.82
0
[0.00%]
PreMarket: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Bicycle Therapeutics Stock (NASDAQ:BCYC)
Bicycle Therapeutics Stock (NASDAQ: BCYC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Expert Ratings For Bicycle Therapeutics
Benzinga Insights
-
Apr 10, 2024, 8:01AM
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 5:22AM
Wednesday, February 21, 2024
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
-
Feb 21, 2024, 1:45PM
Canaccord Genuity Reiterates Buy on Bicycle Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk
-
Feb 21, 2024, 8:57AM
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
Benzinga Insights
-
Feb 21, 2024, 8:00AM
HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $55
Benzinga Newsdesk
-
Feb 21, 2024, 7:04AM
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk
-
Feb 21, 2024, 5:34AM
Tuesday, February 20, 2024
Bicycle Therapeutics Q4 EPS $(1.16) Vs $(1.01) YoY, Sales $5.33M Miss $7.14M Estimate
Benzinga Newsdesk
-
Feb 20, 2024, 7:13AM
Tuesday, February 13, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 13, 2024, 12:31PM
Wednesday, December 20, 2023
Forecasting The Future: 4 Analyst Projections For Bicycle Therapeutics
Benzinga Insights
-
Dec 20, 2023, 8:01AM
JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $32
Benzinga Newsdesk
-
Dec 20, 2023, 7:06AM
Friday, December 15, 2023
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $43
Benzinga Newsdesk
-
Dec 15, 2023, 2:25PM
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Dec 15, 2023, 10:21AM
Thursday, December 14, 2023
Bicycle Therapeutics shares are trading lower. The company announced data updates for BT8009, BT7480 and BT5528.
Benzinga Newsdesk
-
Dec 14, 2023, 11:48AM
Bicycle Therapeutics Provides Data Updates For BT8009, BT7480 And BT5528 Programs, Strategy Overview at First R&D Day
Benzinga Newsdesk
-
Dec 14, 2023, 7:11AM
Thursday, November 30, 2023
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
Lisa Levin
-
Nov 30, 2023, 10:12AM
Thursday, November 16, 2023
9 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Nov 16, 2023, 12:35PM
Wednesday, November 08, 2023
Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Benzinga Newsdesk
-
Nov 8, 2023, 12:03PM
Friday, November 03, 2023
Expert Ratings for Bicycle Therapeutics
Benzinga Insights
-
Nov 3, 2023, 5:00PM
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk
-
Nov 3, 2023, 8:41AM
Thursday, November 02, 2023
Bicycle Therapeutics Q3 EPS $(1.26) Misses $(1.17) Estimate, Sales $5.35M Miss $13.09M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 8:10AM
Thursday, October 19, 2023
Bicycle Therapeutics' Lead Candidate BT8009 For Metastatic Bladder (Urothelial) Cancer, Has Been Selected For Chemistry, Manufacturing And Controls Development And Readiness Pilot Program Launched By FDA
Benzinga Newsdesk
-
Oct 19, 2023, 7:24AM
Tuesday, September 12, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Benzinga Insights
-
Sep 12, 2023, 11:00AM
B. Riley Securities Upgrades Bicycle Therapeutics to Buy, Announces $33 Price Target
Benzinga Newsdesk
-
Sep 12, 2023, 9:54AM
Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Benzinga Newsdesk
-
Sep 12, 2023, 9:04AM
JMP Securities Reiterates Market Outperform on Bicycle Therapeutics, Maintains $44 Price Target
Benzinga Newsdesk
-
Sep 12, 2023, 8:04AM
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $46 Price Target
Benzinga Newsdesk
-
Sep 12, 2023, 5:25AM
Monday, September 11, 2023
Bicycle Therapeutics shares are trading higher after the company announced an expedited development plan for BT8009. B. Riley Securities upgraded the stock from Neutral to Buy.
Bill Haddad
-
Sep 11, 2023, 2:24PM
B. Riley Securities Upgrades Bicycle Therapeutics to Buy, Maintains Price Target to $33
Benzinga Newsdesk
-
Sep 11, 2023, 1:58PM
Bicycle Therapeutics Announced To Proceed With Its Plan To Expedite The Development Of Bt8009 For Metastatic Bladder (Urothelial) Cancer Following Recent Discussions With The FDA, The Study Is Expected To Start In Q1 2024
Benzinga Newsdesk
-
Sep 11, 2023, 7:10AM
Thursday, September 07, 2023
Where Bicycle Therapeutics Stands With Analysts
Benzinga Insights
-
Sep 7, 2023, 3:00PM
Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Benzinga Newsdesk
-
Sep 7, 2023, 10:35AM
Friday, August 04, 2023
Morgan Stanley Reiterates Equal-Weight on Bicycle Therapeutics, Maintains $42 Price Target
Benzinga Newsdesk
-
Aug 4, 2023, 12:46PM
Expert Ratings for Bicycle Therapeutics
Benzinga Insights
-
Aug 4, 2023, 9:00AM
JMP Securities Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $44
Benzinga Newsdesk
-
Aug 4, 2023, 7:21AM
HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target
Benzinga Newsdesk
-
Aug 4, 2023, 6:23AM
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $46
Benzinga Newsdesk
-
Aug 4, 2023, 5:25AM
Thursday, August 03, 2023
EF Hutton Reiterates Buy on Bicycle Therapeutics, Maintains $50 Price Target
Benzinga Newsdesk
-
Aug 3, 2023, 1:38PM
Bicycle Therapeutics' Q2 Cash And Cash Equivalents Were $340.4M
Benzinga Newsdesk
-
Aug 3, 2023, 7:18AM
Bicycle Therapeutics Q2 EPS $(1.41) Misses $(1.29) Estimate, Sales $11.40M Beat $4.58M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 7:17AM
Thursday, July 13, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jul 13, 2023, 1:37PM
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
Lisa Levin
-
Jul 13, 2023, 10:59AM
Bicycle Therapeutics Priced Its Public Offering Of 9.4M American Depositary Shares, Each Representing One Ordinary Share, At $21.25 Per Share, For Gross Proceeds Of Approximately $200M
Benzinga Newsdesk
-
Jul 13, 2023, 4:48AM
Wednesday, July 12, 2023
Bicycle Therapeutics Announces Proposed $200M Public Offering Of American Depositary Shares And Non-Voting Ordinary Shares
Benzinga Newsdesk
-
Jul 12, 2023, 4:01PM
Friday, June 23, 2023
Bicycle Therapeutics Appoints Alethia Young As Chief Financial Officer
Bill Haddad
-
Jun 23, 2023, 7:31AM
Wednesday, May 17, 2023
Bicycle Therapeutics's Return On Capital Employed Insights
Benzinga Insights
-
May 17, 2023, 10:46AM
Thursday, May 11, 2023
14 Analysts Have This to Say About Bicycle Therapeutics
Benzinga Insights
-
May 11, 2023, 11:02AM
JMP Securities Reiterates Market Outperform on Bicycle Therapeutics, Maintains $46 Price Target
Benzinga Newsdesk
-
May 11, 2023, 7:53AM
Wednesday, May 10, 2023
Bayer and Bicycle Therapeutics Enter Collaboration For Development Of Novel Targeted Radionuclide Therapies In Oncology; Bicycle To Receive $45M Upfront Payment And Up To $1.7B In Milestones Plus tiered Royalties
Benzinga Newsdesk
-
May 10, 2023, 7:11AM
Monday, May 08, 2023
Oppenheimer Reiterates Outperform on Bicycle Therapeutics, Maintains $55 Price Target
Benzinga Newsdesk
-
May 8, 2023, 8:30AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch